REDWOOD CITY, Calif., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, at 9:30 a.m. PT at the Westin St. Francis Hotel in San Francisco, CA.
A live and archived webcast of the presentation will be available on the Investor Relations page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.
| CONTACT: | Jean-Frédéric Viret, Ph.D. |
| Chief Financial Officer | |
| Coherus BioSciences, Inc. | |
| jviret@coherus.com | |
| 1 (800) 794-5434 |